Cytotoxic T-cell epitope peptides that specifically attack epstein-barr virus-infected cells and uses thereof
US8481051B2 · kind B2 · utility
14Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2006 |
| Grant date | Jul 9, 2013 |
| Priority date | — |
| Expiry date | Aug 18, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16222
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.